Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:CNTX NASDAQ:GRML NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.05-0.6%$3.31$0.78▼$4.98$133.55M1.772.87 million shs1.55 million shsCNTXContext Therapeutics$1.39-2.1%$2.34$0.56▼$3.62$127.71M1.61706,714 shs498,614 shsGRMLGreenland Mines Ltd. Common Stock$0.29-3.9%$0.43$0.21▼$2.02$35.52M6.943.54 million shs2.58 million shsNRXPNRx Pharmaceuticals$3.84-2.0%$3.19$1.62▼$5.05$139.12M2.141.75 million shs594,787 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-1.95%+2.83%-69.68%-74.45%-70.35%CNTXContext Therapeutics-2.11%-20.57%-41.10%-58.63%+124.09%GRMLGreenland Mines Ltd. Common Stock-3.93%-4.56%-31.06%-44.11%-79.79%NRXPNRx Pharmaceuticals-2.04%-7.25%+30.17%+106.45%+10.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.05-0.6%$3.31$0.78▼$4.98$133.55M1.772.87 million shs1.55 million shsCNTXContext Therapeutics$1.39-2.1%$2.34$0.56▼$3.62$127.71M1.61706,714 shs498,614 shsGRMLGreenland Mines Ltd. Common Stock$0.29-3.9%$0.43$0.21▼$2.02$35.52M6.943.54 million shs2.58 million shsNRXPNRx Pharmaceuticals$3.84-2.0%$3.19$1.62▼$5.05$139.12M2.141.75 million shs594,787 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-1.95%+2.83%-69.68%-74.45%-70.35%CNTXContext Therapeutics-2.11%-20.57%-41.10%-58.63%+124.09%GRMLGreenland Mines Ltd. Common Stock-3.93%-4.56%-31.06%-44.11%-79.79%NRXPNRx Pharmaceuticals-2.04%-7.25%+30.17%+106.45%+10.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.33Hold$6.25492.98% UpsideCNTXContext Therapeutics 2.88Moderate Buy$6.60374.82% UpsideGRMLGreenland Mines Ltd. Common Stock 1.00SellN/AN/ANRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25896.09% UpsideCurrent Analyst Ratings BreakdownLatest GRML, ADCT, CNTX, and NRXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026GRMLGreenland Mines Ltd. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/8/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/4/2026ADCTADC Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.006/4/2026ADCTADC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$6.00 ➝ $2.005/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.004/27/2026NRXPNRx Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $49.004/27/2026NRXPNRx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M1.65N/AN/A($1.50) per share-0.70CNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/A$0.13 per shareN/ANRXPNRx Pharmaceuticals$1.23M113.11N/AN/A($0.54) per share-7.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)GRMLGreenland Mines Ltd. Common Stock-$10.55M-$0.32N/AN/AN/AN/A-109.40%-98.80%N/ANRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.51N/AN/AN/A-202.92%8/17/2026 (Estimated)Latest GRML, ADCT, CNTX, and NRXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026GRMLGreenland Mines Ltd. Common StockN/A-$0.15N/A-$0.15N/AN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A5/5/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 million4/1/2026Q4 2025GRMLGreenland Mines Ltd. Common StockN/A$0.01N/A$0.01N/AN/A3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.20$7.53 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AGRMLGreenland Mines Ltd. Common StockN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.02CNTXContext TherapeuticsN/A8.968.96GRMLGreenland Mines Ltd. Common StockN/A19.7319.73NRXPNRx PharmaceuticalsN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%CNTXContext Therapeutics14.03%GRMLGreenland Mines Ltd. Common Stock20.07%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%CNTXContext Therapeutics4.80%GRMLGreenland Mines Ltd. Common Stock11.30%NRXPNRx Pharmaceuticals6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableGRMLGreenland Mines Ltd. Common Stock5121.24 million107.54 millionN/ANRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableGRML, ADCT, CNTX, and NRXP HeadlinesRecent News About These CompaniesNRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per ShareJune 10 at 3:11 PM | insidermonkey.comNRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Lowered by Wall Street ZenJune 6, 2026 | americanbankingnews.comNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.June 5, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ OptionJune 5, 2026 | markets.businessinsider.comNRx Pharmaceuticals Announces $20 Million Public Stock OfferingJune 4, 2026 | tipranks.comNRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS TherapeuticsJune 4, 2026 | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' OptionJune 4, 2026 | globenewswire.comNRx Pharmaceuticals Plans Underwritten Public Stock OfferingJune 4, 2026 | theglobeandmail.comNRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 MillionJune 3, 2026 | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockJune 3, 2026 | globenewswire.comNRx Pharmaceuticals (NRXP) stock fell 19% after hours on Tuesday: Here's whyJune 3, 2026 | msn.comNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockJune 2, 2026 | globenewswire.comQ2 EPS Forecast for NRx Pharmaceuticals Decreased by AnalystJune 1, 2026 | marketbeat.comNRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026May 28, 2026 | globenewswire.comNRx (NRXP) Q1 2026 Earnings Call TranscriptMay 27, 2026 | fool.comNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemMay 27, 2026 | globenewswire.comHere is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | insidermonkey.comNRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market UncertaintyMay 20, 2026 | seekingalpha.comNRx Pharmaceuticals Q1 Earnings Call HighlightsMay 18, 2026 | marketbeat.comNRx Pharmaceuticals Reports Q1 2026 Milestones, Including Advancements in Ketamine and NRX-101 DevelopmentMay 18, 2026 | quiverquant.comQNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 18, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRML, ADCT, CNTX, and NRXP Company DescriptionsADC Therapeutics NYSE:ADCT$1.05 -0.01 (-0.57%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$1.05 0.00 (-0.38%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Context Therapeutics NASDAQ:CNTX$1.39 -0.03 (-2.11%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.34 -0.05 (-3.38%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Greenland Mines Ltd. Common Stock NASDAQ:GRML$0.29 -0.01 (-3.93%) As of 06/12/2026 04:00 PM EasternGreenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.NRx Pharmaceuticals NASDAQ:NRXP$3.84 -0.08 (-2.04%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.91 +0.07 (+1.82%) As of 06/12/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
